Olaparib Without ADT May Elicit High Response Rates in Prostate Cancer Subset
Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer with BRCA2 alterations.
Related Articles
Induction Chemotherapy Combination Boosts PFS/OS in Cervical Cancer
Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.
OncLive’s October Roundup of Key FDA Approvals in Oncology
Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.
Olaparib Without Androgen Deprivation for Biochemically Recurrent Prostate Cancer Following Prostatectomy
This nonrandomized controlled trial aims to determine the activity of olaparib monotherapy among patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy.
Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches
John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients?
Nature Reviews Clinical Oncology – A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appetite, ingestive behaviour,…
Immunotherapy Updates Unlocked: An Interactive Digital Engagement Showcase
Watch live to hear the latest current and emerging clinical data on the use of immunotherapy in patients with melanoma, hepatocellular carcinoma (HCC), and l…
New insights into the biology of T-cell lymphomas
Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current stat
iwNHL 2024 | VJHemOnc
The 21st International Workshop on Non-Hodgkin Lymphoma (iw NHL) took place in Nice, France, on 19 – 21 September, 2024. Esteemed experts convened to discuss…
FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
A modern view of LGL leukemia
Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current stat